Improved approach to identify cancer-associated autoantigens.
The failure to identify biomarkers of clinical significance for cancer diagnosis and prognosis generated a great deal of skepticism in regard to the usefulness of autoantibody-based methods. SEREX was a major advancement in immunoscreening that resulted in the identification of a large group of autoantigens recognized by cancer sera. However, few SEREX-defined autoantigens have proven to have definitive diagnostic value in clinical practice. Often, the identified antigens are patient-specific rather than tumor-specific and many tumor-associated antigens are rare in expression libraries made from non-autologous cells. Since autoantibodies are part of the normal immune response, it can be difficult to single out tumor-associated antibodies from the scores of irrelevant patient-specific responses. In our view, any practical approach for identifying cancer-related autoantigens must include an integral strategy for demonstrating tumor relevance early in the screening process. Care must also be taken not to exclude potentially important autoantibodies by pre-screening manipulations to patient sera. We have introduced substantial modifications in SEREX, designed to minimize confounding effects of unrelated autoantibodies and to eliminate steps that preclude the identification of cancer-related autoantigens commonly recognized by cancer sera. In addition, we incorporate methodology to identify candidate antigens that have potential diagnostic or prognostic value prior to their molecular cloning and characterization.
Fernández Madrid
Félix
F
University Health Center, 4H, Department of Internal Medicine, Division of Rheumatology, Wayne State University, Detroit, MI 48201, USA. fmadrid@intmed.wayne.edu
Tang
Naimei
N
Alansari
Huda
H
Karvonen
Robert L
RL
Tomkiel
John E
JE
D000951:Antigens, Neoplasm / Q000032:analysis* / Q000097:blood; D001323:Autoantibodies / Q000276:immunology; D001324:Autoantigens / Q000032:analysis* / Q000097:blood; D001943:Breast Neoplasms / Q000175:diagnosis / Q000276:immunology; D009369:Neoplasms / Q000175:diagnosis*
D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens